# Cabaletta Bio, Inc.: financial statements, quarterly

CABA · Nasdaq · CIK 1759138 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/caba.md) · [Financials](/companies/caba/financials.md) · [Filings](/companies/caba/filings.md) · [Insiders](/companies/caba/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/caba/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [13.8](/filings/0000950170-24-126733.md) | [17.4 d](/filings/0000950170-25-047201.md) | [22.0](/filings/0000950170-25-071971.md) | [23.4](/filings/0000950170-25-104573.md) | [26.3](/filings/0001193125-25-273280.md) | [25.5 d](/filings/0001759138-26-000011.md) | [29.0](/filings/0001759138-26-000026.md) | [37.6](/filings/0001759138-26-000039.md) | [39.8](/filings/0001193125-25-273280.md) | [36.2 d](/filings/0001759138-26-000011.md) | [37.4](/filings/0001759138-26-000026.md) | [44.4](/filings/0001759138-26-000039.md) |
| Operating income | $m | [(18.7)](/filings/0000950170-24-126733.md) | [(23.1) d](/filings/0000950170-25-047201.md) | [(28.0)](/filings/0000950170-25-071971.md) | [(30.3)](/filings/0000950170-25-104573.md) | [(33.0)](/filings/0001193125-25-273280.md) | [(33.8) d](/filings/0001759138-26-000011.md) | [(37.1)](/filings/0001759138-26-000026.md) | [(45.9)](/filings/0001759138-26-000039.md) | [(46.6)](/filings/0001193125-25-273280.md) | [(42.6) d](/filings/0001759138-26-000011.md) | [(44.3)](/filings/0001759138-26-000026.md) | [(52.0)](/filings/0001759138-26-000039.md) |
| Interest expense | $m | not reported | not reported | [0.0](/filings/0000950170-25-071971.md) | [0.0](/filings/0000950170-25-104573.md) | [0.0](/filings/0001193125-25-273280.md) | [0.7 d](/filings/0001759138-26-000011.md) | [0.3](/filings/0001759138-26-000026.md) | [0.6](/filings/0001759138-26-000039.md) | [0.6](/filings/0001193125-25-273280.md) | [0.6 d](/filings/0001759138-26-000011.md) | [0.6](/filings/0001759138-26-000026.md) | [0.5](/filings/0001759138-26-000039.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-126733.md) | not reported | [0.0](/filings/0000950170-25-071971.md) | [0.0](/filings/0000950170-25-104573.md) | [0.0](/filings/0001193125-25-273280.md) | [0.0 d](/filings/0001759138-26-000011.md) | [0.0](/filings/0001759138-26-000026.md) | [0.0](/filings/0000950170-25-104573.md) | [0.0](/filings/0001193125-25-273280.md) | [0.0 d](/filings/0001759138-26-000011.md) | [0.0](/filings/0001759138-26-000026.md) | [0.0](/filings/0001759138-26-000039.md) |
| Net income | $m | [(16.4)](/filings/0000950170-24-126733.md) | [(20.9) d](/filings/0000950170-25-047201.md) | [(25.0)](/filings/0001193125-25-273280.md) | [(27.6)](/filings/0001193125-25-273280.md) | [(30.6)](/filings/0001193125-25-273280.md) | [(32.6) d](/filings/0001759138-26-000011.md) | [(35.9)](/filings/0001759138-26-000039.md) | [(45.1)](/filings/0001759138-26-000039.md) | [(44.9)](/filings/0001193125-25-273280.md) | [(41.9) d](/filings/0001759138-26-000011.md) | [(43.5)](/filings/0001759138-26-000039.md) | [(51.0)](/filings/0001759138-26-000039.md) |
| Diluted EPS | $ per share | [(0.37)](/filings/0000950170-24-126733.md) | not reported | [(0.51)](/filings/0000950170-25-071971.md) | [(0.56)](/filings/0000950170-25-104573.md) | [(0.62)](/filings/0001193125-25-273280.md) | not reported | [(0.71)](/filings/0001759138-26-000026.md) | [(0.73)](/filings/0001759138-26-000039.md) | [(0.44)](/filings/0001193125-25-273280.md) | not reported | [(0.39)](/filings/0001759138-26-000026.md) | [(0.34)](/filings/0001759138-26-000039.md) |
| Basic EPS | $ per share | [(0.37)](/filings/0000950170-24-126733.md) | not reported | [(0.51)](/filings/0000950170-25-071971.md) | [(0.56)](/filings/0000950170-25-104573.md) | [(0.62)](/filings/0001193125-25-273280.md) | not reported | [(0.71)](/filings/0001759138-26-000026.md) | [(0.73)](/filings/0001759138-26-000039.md) | [(0.44)](/filings/0001193125-25-273280.md) | not reported | [(0.39)](/filings/0001759138-26-000026.md) | [(0.34)](/filings/0001759138-26-000039.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [116](/filings/0000950170-23-061528.md) | [193](/filings/0000950170-25-047201.md) | [175](/filings/0000950170-24-060045.md) | [179](/filings/0000950170-24-093325.md) | [171](/filings/0000950170-24-126733.md) | [164](/filings/0001759138-26-000011.md) | [132](/filings/0000950170-25-071971.md) | [146](/filings/0000950170-25-104573.md) | [60.2](/filings/0001193125-25-273280.md) | [83.0](/filings/0001759138-26-000039.md) | [117](/filings/0001759138-26-000026.md) | [225](/filings/0001759138-26-000039.md) |
| Current assets | $m | [166](/filings/0000950170-23-061528.md) | [244](/filings/0000950170-25-047201.md) | [227](/filings/0000950170-24-060045.md) | [206](/filings/0000950170-24-093325.md) | [186](/filings/0000950170-24-126733.md) | [167](/filings/0001759138-26-000011.md) | [135](/filings/0000950170-25-071971.md) | [198](/filings/0000950170-25-104573.md) | [165](/filings/0001193125-25-273280.md) | [139](/filings/0001759138-26-000039.md) | [122](/filings/0001759138-26-000026.md) | [231](/filings/0001759138-26-000039.md) |
| Total assets | $m | [173](/filings/0000950170-23-061528.md) | [254](/filings/0000950170-25-047201.md) | [240](/filings/0000950170-24-060045.md) | [217](/filings/0000950170-24-093325.md) | [204](/filings/0000950170-24-126733.md) | [185](/filings/0001759138-26-000011.md) | [165](/filings/0000950170-25-071971.md) | [225](/filings/0000950170-25-104573.md) | [190](/filings/0001193125-25-273280.md) | [165](/filings/0001759138-26-000039.md) | [148](/filings/0001759138-26-000026.md) | [257](/filings/0001759138-26-000039.md) |
| Current liabilities | $m | [10.6](/filings/0000950170-23-061528.md) | [16.0](/filings/0000950170-25-047201.md) | [18.0](/filings/0000950170-24-060045.md) | [17.9](/filings/0000950170-24-093325.md) | [22.9](/filings/0000950170-24-126733.md) | [27.1](/filings/0001759138-26-000011.md) | [34.0](/filings/0000950170-25-071971.md) | [41.5](/filings/0000950170-25-104573.md) | [45.7](/filings/0001193125-25-273280.md) | [50.2](/filings/0001759138-26-000039.md) | [41.5](/filings/0001759138-26-000026.md) | [39.9](/filings/0001759138-26-000039.md) |
| Total liabilities | $m | [12.4](/filings/0000950170-23-061528.md) | [17.5](/filings/0000950170-25-047201.md) | [18.7](/filings/0000950170-24-060045.md) | [17.9](/filings/0000950170-24-093325.md) | [30.2](/filings/0000950170-24-126733.md) | [32.7](/filings/0001759138-26-000011.md) | [43.6](/filings/0000950170-25-071971.md) | [46.0](/filings/0000950170-25-104573.md) | [50.3](/filings/0001193125-25-273280.md) | [53.0](/filings/0001759138-26-000039.md) | [44.8](/filings/0001759138-26-000026.md) | [46.1](/filings/0001759138-26-000039.md) |
| Shareholders' equity | $m | [161](/filings/0000950170-24-126733.md) | [236](/filings/0001759138-26-000011.md) | [222](/filings/0001193125-25-273280.md) | [200](/filings/0001193125-25-273280.md) | [174](/filings/0001193125-25-273280.md) | [152](/filings/0001759138-26-000039.md) | [122](/filings/0001759138-26-000039.md) | [178](/filings/0001759138-26-000039.md) | [139](/filings/0001193125-25-273280.md) | [112](/filings/0001759138-26-000039.md) | [103](/filings/0001759138-26-000039.md) | [211](/filings/0001759138-26-000039.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(12.6) d](/filings/0000950170-24-126733.md) | [(16.4) d](/filings/0000950170-25-047201.md) | [(24.0)](/filings/0000950170-25-071971.md) | [(20.8) d](/filings/0000950170-25-104573.md) | [(20.3) d](/filings/0001193125-25-273280.md) | [(23.1) d](/filings/0001759138-26-000011.md) | [(30.8)](/filings/0001759138-26-000026.md) | [(30.4) d](/filings/0001759138-26-000039.md) | [(34.5) d](/filings/0001193125-25-273280.md) | [(35.3) d](/filings/0001759138-26-000011.md) | [(42.6)](/filings/0001759138-26-000026.md) | [(41.5) d](/filings/0001759138-26-000039.md) |
| Capital expenditure | $m | [0.1 d](/filings/0000950170-24-126733.md) | [0.2 d](/filings/0000950170-25-047201.md) | [0.8](/filings/0000950170-25-071971.md) | [0.8 d](/filings/0000950170-25-104573.md) | [0.3 d](/filings/0001193125-25-273280.md) | [0.4 d](/filings/0001759138-26-000011.md) | [0.8](/filings/0001759138-26-000026.md) | [0.2 d](/filings/0001759138-26-000039.md) | [0.1 d](/filings/0001193125-25-273280.md) | [0.2 d](/filings/0001759138-26-000011.md) | [0.0](/filings/0001759138-26-000026.md) | [0.0 d](/filings/0001759138-26-000039.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [50.7](/filings/0001759138-26-000026.md) | [61.9](/filings/0001759138-26-000039.md) | [112](/filings/0001759138-26-000026.md) | [151](/filings/0001759138-26-000039.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 169,545,445 at 2026-08-07, from the cover of the [10-Q filed 2026-08-13](/filings/0001759138-26-000039.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.